| Texto completo | |
| Autor(es): |
Lago, Eloi M.
[1]
;
Xavier, Rogerio P.
[1]
;
Teixeira, Thaina R.
[1]
;
Silva, Livia M.
[2]
;
da Silva Filho, Ademar A.
[2]
;
de Moraes, Josue
[1]
Número total de Autores: 6
|
| Afiliação do(s) autor(es): | [1] Univ Universus Veritas UNIVERITAS UNG, Nucl Pesquisa Doencas Negligenciadas, Praca Tereza Cristina 229, BR-07023070 Guarulhos, SP - Brazil
[2] Univ Fed Juiz de Fora, Dept Ciencias Farmaceut, Juiz De Fora, MG - Brazil
Número total de Afiliações: 2
|
| Tipo de documento: | Artigo de Revisão |
| Fonte: | Future Medicinal Chemistry; v. 10, n. 1, p. 89-120, JAN 2018. |
| Citações Web of Science: | 14 |
| Resumo | |
Praziquantel has remained the drug of choice for schistosomiasis chemotherapy for almost 40 years. The pressing need to develop a new antischistosomal drug may necessitate exploring and filtering chemotherapeutic history to search for the most promising ones. In this context, this review attempts to summarize all progress made in schistosomiasis chemotherapy from the early 20th century (mid-1910s) to 2016. We gathered almost 100 compounds providing information on therapeutic action, specifically covering at least first in vivo studies in animal model and in vitro. Pharmacokinetic and toxicity profiles of antischistosomal agents were also described. Preclinical studies indicate a handful of promising future candidates. (AU) | |
| Processo FAPESP: | 16/22488-3 - Reposicionamento de fármacos para doenças negligenciadas: identificação de novos agentes anti-helmínticos |
| Beneficiário: | Josué de Moraes |
| Modalidade de apoio: | Auxílio à Pesquisa - Regular |